Pyxis Oncology Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.0%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$1.22next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents (including short-term investments) Quarterly42.5MTarget: Sufficient to fund operations into Q4 2026
Quarterly Research and Development (R&D) Expenses Quarterly20MTarget: Maintain clinical execution within runway constraints
Quarterly Net Loss Quarterly-23.3MTarget: Manage cash burn rate to preserve capital
Watch Items
- MICVO Phase 1 Monotherapy 2L+ R/M HNSCC Data UpdateTrigger: Mid-year 2026 data release focusing on patients treated at or below the December 2025 dose cap (5.4 mg/kg IV Q3W)Action: Evaluate safety, tolerability, and efficacy (ORR) to confirm if the dose cap successfully mitigates toxicities while maintaining therapeutic benefit.
- MICVO + Pembrolizumab Phase 1/2 Combination Data UpdateTrigger: Second half of 2026 data release in 1L R/M HNSCC patientsAction: Assess synergistic anti-tumor activity and safety profile of the combination to support potential registrational trial designs.
- Cash Runway and Financing NeedsTrigger: Cash runway projected to extend only into the fourth quarter of 2026Action: Monitor for strategic partnerships, licensing agreements, or dilutive equity offerings to extend the operational runway beyond Q4 2026.
- Permanent CEO AppointmentTrigger: Board search following the transition to Interim CEO Thomas CivikAction: Assess the strategic direction and clinical development experience of the newly appointed permanent executive leadership.
Research as of 20 Jun 2026